A month has gone by since the last earnings report for Blueprint Medicines (BPMC - Free Report) . Shares have added about 7.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Blueprint Medicines due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Blueprint Medicines Q1 Earnings & Sales Lag Estimates
Blueprint Medicines incurred a loss of $1.98 per share in the first quarter of 2019, wider than the Zacks Consensus Estimate of $1.83 and also the year-ago quarter’s loss of $1.29 due to higher operating costs.
Collaboration revenues, comprising the company’s total revenues, came in at $0.7 million, down 30% year over year. Moreover, the top line missed the Zacks Consensus Estimate of $2 million.
Blueprint Medicines has no approved product in its portfolio at the moment. The revenues generated by the company are all related to its partnership with Roche and CStone Pharmaceuticals for the development and commercialization of its pipeline candidates.
Quarter in Detail
In the reported quarter, research and development expenses were $74.3 million, up 48.6% from the year-ago period’s figure, mainly owing to higher spending associated with the lead candidates’ development and higher personnel costs.
General and administrative expenses were $16.6 million, up 67.7% year over year on account of higher personnel costs, professional fees and pre-commercial planning activities.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. The consensus estimate has shifted -5.4% due to these changes.
Currently, Blueprint Medicines has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Charting a somewhat similar path, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Estimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Blueprint Medicines has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.